Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib versus nilotinib in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
2024-510947-71-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Asciminib with Nilotinib (2 arms). Primary endpoint: Time to discontinuation of study treatment due to adverse event. Planned start Jun 2024; status: authorised.
02
Drugs
asciminibnilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-510947-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510947-71-00.